On May 30, 2026, RNACure welcomed a student delegation from Shenzhen University of Technology (SUSTech) for a campus-enterprise exchange. Led by Deputy Party Secretary Wang Hui, over twenty faculty and students visited the company for in-depth discussions on technology exchange, scientific research collaboration, and talent development.
RNACure, focused on innovative mRNA drug research and development, has established comprehensive R&D, process optimization, and industrialization systems. The company is deeply engaged in frontier areas including infectious disease vaccines, tumor immunotherapy, and rare disease therapeutics. RNACure has long promoted industry-academia-research collaborative innovation, actively partnering with university resources for technology breakthroughs and成果转化.
During the exchange event, Deputy General Manager Lu Jing and the core team presented the company's technology platforms, R&D systems, and industrial布局, sharing insights on core mRNA R&D technologies, process standards, and industry development trends. The discussions effectively connected theory with industrial applications, laying the groundwork for long-term scientific collaboration and talent engagement between the two parties.
The visiting team toured the company's standardized research laboratories, gaining firsthand understanding of mRNA R&D workflows, experimental platforms, and quality control management systems.
This event achieved bidirectional empowerment between the university and the enterprise. RNACure will continue to deepen strategic university partnerships, open its research technology platforms, and advance collaborative innovation in talent development and成果转化.
